Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be between 50 - 59 years of age~* No fever on day of vaccination~* Females of reproductive potential must be willing to use acceptable form of birth control~Exclusion Criteria:~* Have received chicken pox or shingles vaccine~* Have already had shingles~* Have recently had another vaccination~* Pregnant or breast feeding. Have participated in another research study in the last 30 days~* You are taking certain antiviral drugs~* History of allergic reaction to any vaccine component, including gelatin or neomycin

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Zostavax™ (Type: EXPERIMENTAL): Participants randomized to receive Zoster Vaccine, Live (Zostavax™).
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to receive Placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).